MedWatch

Qufora expects French approval in 2022, trains sights on million-dollar business

FRENCH ELECTION: An aging population and a gradual shift towards the idea of treating people in their own homes has led to intense work for Danish medtech firm Qufora, which is aiming for a revenue of DKK 20-40m (USD 2.9–5.9m) in the nearest future. ”France is our most underexploited close market,” says Qufora’s CEO.

”There are no other markets that we’d rather invest in," says CEO of Qufora Lena Ehmsen Lachenmeier | Photo: Qufora / PR

BRUSSELS – the unprofitable market for ensuring more independence for millions of French people in their autumn years will be turned turned into a growth leg in the future, declares Danish medtech firm Qufora, which is betting heavily on exports to the market to its south.

”France is our most underexploited close market, so if we are to increase our footprint in Europe, that will be an important place to enter,” CEO of Qufora Lena Ehmsen Lachenmeier tells MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs